pritelivir
Sign in to saveAlso known as BAY 57-1293
Pritelivir (development codes AIC316 or BAY 57-1293) is a direct-acting antiviral drug in development for the treatment of herpes simplex virus infections (HSV). This is particularly important in immune compromised patients. It is currently in Phase III clinical development by the German biopharmaceutical company AiCuris Anti-infective Cures AG. US FDA granted fast track designation for pritelivir in 2017 and breakthrough therapy designation 2020.
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 402.082
Show 2 more facts
- chemical formula
- C₁₈H₁₈N₄O₃S₂
- canonical SMILES
- CC1=C(SC(=N1)N(C)C(=O)CC2=CC=C(C=C2)C3=CC=CC=N3)S(=O)(=O)N
Sources (2)
via Wikidata · CC0
~4 min read
Encyclopedic overview
11 sectionsContents
- Medical use
- HSV in immunocompromised patients
- Standard of care treatments
- Resistance to standard treatments
- Clinical research
- Completed phase II clinical trials in otherwise healthy patients with genital herpes
- Ongoing phase II / phase III clinical trials with pritelivir
- Pharmacology
- Mechanism of action
- See also
- References
Pritelivir (development codes AIC316 or BAY 57-1293) is a direct-acting antiviral drug in development for the treatment of herpes simplex virus infections (HSV). This is particularly important in immune compromised patients. It is currently in Phase III clinical development by the German biopharmaceutical company AiCuris Anti-infective Cures AG. US FDA granted fast track designation for pritelivir in 2017 and breakthrough therapy designation 2020.
== Medical use == Pritelivir is currently being developed for the treatment of immunocompromised patients with mucocutaneous HSV lesions that are resistant to acyclovir.
Excerpted from Wikipedia’s “pritelivir” article, available under the CC BY-SA 4.0 licence.